DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = A-623 or AMG 623; A07EA06; ACE Inhibitor or Angiotensin receptor antagonist; ACE inhibitor; ACE inhibitor + statin; ACE/ARB; ACEI/ARB and corticosteroids; ACEi; ACTH; ACTH (Acthar) Gel; ALN-CC5; APL-2; ARB; ATACICEPT; ATG-F; AVB-S6-500; AZATHIOPRINE; Abelmoschus manihot; Acteoside; Acthar; Acthar 80 unit injection; Aliskiren; Allopurinol; Angiotensin; Angiotensin II; Angiotensin blockade; Artesunate; Atacicept; Atacicept 25 mg; Atacicept 75 mg; Atacicept150mg; Atacicept25mg; Atacicept75mg; Atrasentan; Azathioprine; BENLYSTA® (belimumab); BION-1301 Multiple Doses; BION-1301 Single Dose; BUDESONIDE; Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Belimumab; Benlysta; Blisibimod; Blisibimod Injection; Blood sample; Bortezomib; Bortezomib (Velcade®); Budesonide; CCX168; CEMDISIRAN; CYCLOPHOSPHAMIDE; Calcitriol; Cemdisiran; Chinese Herb Prescription Granule plus prednisone; Cilazapril; Corticosteroid; Corticotherapy; Cyclophosphamid; Cyclophosphamide; Decortin H; Dipyridamole; ENALAPRIL VALSARTAN METHYLPREDNISONE; Enalapril; FOS; FOSTAMATINIB DISODIUM; Fecal microbiota transplantation; Fish oil; Fostamatinib; Fostamatinib 100 mg; Fostamatinib 100 mg tablet; Fostamatinib 150 mg; Fostamatinib 150 mg tablet; Fostamatinib Disodium tablet 100 mg; Fostamatinib Disodium tablet 150 mg; GSK1550188; Gastrus; High Dose-VIS649; Hormone (prednisone); Human soluble recombinant Fc-gamma receptor IIB; Hydroxychloroquine; Hydroxychloroquine Sulfate; IONIS-FB-LRx; IRBESARTAN; Immunosuppressants; Immunosuppressive treatment; Infusion of ADR-001 (Mesenchymal stem cell); Inhibace/Cozaar; Intervention for incipient patients at low risk of disease progression; Intervention for patients at high risk of disease progression; Intravenous Rituximab; Iptacopan; Irbesartan; Irbesartan approved in the Netherlands; Irbesartan tablets; Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03; Irbesartan tablets (NDC# 0955-1041-90 approved in the USA); Irbesartan tablets (NDC# 43547-375-50 approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC; LNP023; Leflunomide; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Lisinopril; Losartan; Low Dose-VIS649; Low antigen content diet; METHYLPREDNISOLONE; METHYLPREDNISOLONE MYLAN Générique; MMF; Medium Dose-VIS649; Menatetrenone; Methylprednisolon; Methylprednisolone; Methylprednisolone (MP) or prednisone (pred); Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisone; Mizoribine; Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH); Mycophenolat-Natrium; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF); Mycophenolate mofetil; Mycophenolate mofetil (MMF); Mycophenolate mofetil plus lower dose of Prednisone; Mycophenolate sodium; Mycophenolic acid; Mycophenolic sodium; Myfortic; Myfortic 180mg Tablets; Myfortic 360mg Tablets; NEFECON; Narsoplimab; Nefecon; OMS721; OMS721 (narsoplimab); OPL-CCL2-LPM; Omega-3; Omega-3 Fatty Acid Fish Oil Supplement; Omega-3 fatty acid; Omega-3 fatty acid ethylester90; Other: Optimized Supportive Care; Other: Vehicle (D5W or saline); Other: continue their usual therapy; Other: intensive supportive care; Over-encapsulated 150 mg Irbesartan Tablets; Over-encapsulated Irbesartan; Over-encapsulated Irbesartan Tablets; Over-encapsulated Irbesartan tablets; PREDNISOLONE; PREDNISONE; PREDNISONE ARROW 20mg; PREDNISONE ARROW 5 mg; Paricalcitol; Placebo; Potassium; Prednisolon; Prednisolone; Prednisone; Prednisone + Inhibace/Cozaar; Prednisone 5 mg; Prednisone alone; Prednisone and cyclophosphamide; Prednisone in full dose; Prednisone or Prednisolone; Prednisone plus cyclophosphamide; ProTectis; Probucol; Procedure: Plasma Exchange (PE); R935788; RAPAMUNE; RAS; RAS 2410; RC18 160mg; RC18 240mg; RE-021; Ramipril; Rapamune; Reh-acteoside; Renin Angiotensin system (RAS) blockade; Risedronate; Rituximab; SIROLIMUS; SM101; SPARSENTAN; Simulect; Simvastatin; Sirolimus; Sirolimus (study drug)+ACE inhibitor + statin; Sparsentan; Sparsentan tablets; Sparsentan tablets/ Over-encapsulated Sparsentan tablets; Sparsentan tablets/Over-encapsulated Sparsentan tablets; Sparsentan tablets/Overencapsulated Sparsentan tablets; Steroids; Steroids plus azathioprine; Sulfate; Supportive and immunosuppressive therapy; Supportive therapy; Supportive therapy with: ACE-inhibitor / ARB / Statin; Tacrolimus; Tailored diet; Telmisartan; The Yi-Qi-Qing-Jie herbal compound; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii (TW); VIS649; Valsartan; WM (Shentong Granules); Warfarin;  LNP023 HYDROCHLORIDE SALT

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04525729 (ClinicalTrials.gov)	July 1, 2020	17/8/2020	Rituximab and RASi in Patients With IgAN	A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy	IgA Nephropathy	Drug: Rituximab;Drug: RAS 2410	CHENNAN	NULL	Recruiting	18 Years	75 Years	All	116	Phase 4	China
2	NCT03188887 (ClinicalTrials.gov)	February 20, 2018	2/5/2017	Treatment of IgA Nephropathy According to Renal Lesions	Treatment of IgA Nephropathy According to Renal Lesions	IgA Nephropathy	Drug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockade	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	N/A	All	122	Phase 3	France
3	ChiCTR-TRC-09000338	2009-04-01	2009-02-23	Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy	Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy	IgA nephropathy	Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;	The First Affiliated Hospital of Zhejiang University	NULL	Completed	18	70	Male	Group A:60;Group B:60;		China
4	EUCTR2005-003885-40-IT (EUCTR)	18/10/2005	15/01/2007		ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria -	The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders	Product Name: Ramipril INN or Proposed INN: Ramipril Product Name: Irbesartan INN or Proposed INN: Irbesartan	AZIENDA OSPEDALIERA PROVINCIALE DI LECCO	NULL	Not Recruiting			Female: yes Male: yes			Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04525729
(ClinicalTrials.gov)

July 1, 2020

17/8/2020

Rituximab and RASi in Patients With IgAN

A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy

IgA Nephropathy

Drug: Rituximab;Drug: RAS 2410

CHENNAN

NULL

Recruiting

18 Years

75 Years

All

116

Phase 4

China

NCT03188887
(ClinicalTrials.gov)

February 20, 2018

2/5/2017

Treatment of IgA Nephropathy According to Renal Lesions

IgA Nephropathy

Drug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockade

Assistance Publique - Hôpitaux de Paris

NULL

Recruiting

18 Years

N/A

All

122

Phase 3

France

ChiCTR-TRC-09000338

2009-04-01

2009-02-23

Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy

IgA nephropathy

Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;

The First Affiliated Hospital of Zhejiang University

NULL

Completed

Male

Group A:60;Group B:60;

China

EUCTR2005-003885-40-IT
(EUCTR)

18/10/2005

15/01/2007

ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria -

The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented
MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders

Product Name: Ramipril
INN or Proposed INN: Ramipril
Product Name: Irbesartan
INN or Proposed INN: Irbesartan

AZIENDA OSPEDALIERA PROVINCIALE DI LECCO

NULL

Not Recruiting

Female: yes
Male: yes

Italy